CD47 and non-Hodgkin lymphoma: (4) ALX148 is a fusion protein that targets CD47 and is currently being evaluated in several clinical trials, including a phase I/II trial for patients with advanced solid tumors [17] and a phase I trial for patients with relapsed or refractory non-Hodgkin’s lymphoma [52].